Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for non-alcoholic fatty liver disease
IRCT20110727007134N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Fasting blood sugar, Total cholesterol and 6 more. Started Jan 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20110727007134N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110727007134N2.